At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRFX PRF Technologies Ltd.
Post-Mkt 06-15 19:24:38 EDT
2.49
+1.13
+83.09%
盘后1.90
-0.59-23.69%
19:24 EDT
High3.94Low1.36Vol47.08M
Open1.36D1 Closing1.36Amplitude189.71%
Mkt Cap2.16MTradable Cap2.01MTotal Shares868.80K
T/O131.72MT/O Rate5,820.62%Tradable Shares808.80K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:51 PM
Reuters  ·  02:51
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:51 PM
Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push
Benzinga  ·  05-31
Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push
Why Is Penny Stock PRF Technologies (PRFX) Up Today?
TIPRANKS  ·  05-29
Why Is Penny Stock PRF Technologies (PRFX) Up Today?
Top Premarket Gainers
MT Newswires Live  ·  05-29
Top Premarket Gainers
PRF Technologies announces results from study comparing PRF-110 to Zynrelef
TIPRANKS  ·  05-26
PRF Technologies announces results from study comparing PRF-110 to Zynrelef
PRF Technologies says PRF-110 matches Zynrelef in 72-hour pig post-surgery pain study
Reuters  ·  05-26
PRF Technologies says PRF-110 matches Zynrelef in 72-hour pig post-surgery pain study
Prf Technologies Announces Prf-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
THOMSON REUTERS  ·  05-26
Prf Technologies Announces Prf-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
Prf Technologies Ltd - Prf-110 Achieves Sustained Analgesia With Ropivacaine-Only, Nsaid-Free Formulation
THOMSON REUTERS  ·  05-26
Prf Technologies Ltd - Prf-110 Achieves Sustained Analgesia With Ropivacaine-Only, Nsaid-Free Formulation
Prf Technologies Ltd - Prf-110 Shows Consistent Safety and Tolerability in Preclinical Pig Study
THOMSON REUTERS  ·  05-26
Prf Technologies Ltd - Prf-110 Shows Consistent Safety and Tolerability in Preclinical Pig Study
PRF Technologies sells 24,384 unregistered shares to Yorkville for fees
Reuters  ·  05-08
PRF Technologies sells 24,384 unregistered shares to Yorkville for fees
PRF Technologies announces FDA clearance of OcuRing-K NDA
TIPRANKS  ·  04-28
PRF Technologies announces FDA clearance of OcuRing-K NDA
PRF wins FDA IND clearance for OcuRing-K Phase II cataract trial
Reuters  ·  04-28
PRF wins FDA IND clearance for OcuRing-K Phase II cataract trial
Prf Technologies Ltd - to Initiate Phase Ii Trial in U.S. With Enrollment Expected in H2 2026
THOMSON REUTERS  ·  04-28
Prf Technologies Ltd - to Initiate Phase Ii Trial in U.S. With Enrollment Expected in H2 2026
Prf Technologies Announces FDA Clearance of Ind Application for Ocuring™-K Phase Ii Clinical Trial
THOMSON REUTERS  ·  04-28
Prf Technologies Announces FDA Clearance of Ind Application for Ocuring™-K Phase Ii Clinical Trial
What's Going On With Pharma Company PRF Technologies On Tuesday?
Benzinga  ·  04-07
What's Going On With Pharma Company PRF Technologies On Tuesday?
Top Premarket Gainers
MT Newswires Live  ·  04-06
Top Premarket Gainers
Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses
Reuters  ·  03-27
Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses
PRF Technologies In FY25 Had ~$4.1M In Cash, Cash Equivalents, Short-Term Deposits And Restricted Cash And Positive Working Capital Of ~$1.9M
Benzinga  ·  03-27
PRF Technologies In FY25 Had ~$4.1M In Cash, Cash Equivalents, Short-Term Deposits And Restricted Cash And Positive Working Capital Of ~$1.9M
Prf Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
THOMSON REUTERS  ·  03-27
Prf Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
PainReform Ltd FY Net Income USD -4.8 Million
THOMSON REUTERS  ·  03-27
PainReform Ltd FY Net Income USD -4.8 Million

Introduction

Company Name.
PRF Technologies Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Issue price:
--